ORIC-533, a Small Molecule CD73 Inhibitor with Best-in-Class Properties, Reverses Immunosuppression and Has Potential as an Immunomodulatory Therapy in Patients with Multiple Myeloma


ORIC Pharmaceuticals, 240 E Grand Ave, P. 2, South San Francisco, CA 94080; Dana-Farber Cancer Institute, 45 Brookline Avenue, Boston MA 02215, USA

CD73 Mediates Immunosuppression and Therapeutic Resistance via Adenosine Production

1. Discovery of CD73 Inhibitors that Potently Suppress Adenosine Production

2. ORIC Inhibitors Restore T-cell Function More Potently than Other Adenosine Pathway Inhibitors

3. ORIC’s Potent AMP-competitive Inhibitors are Active in a High AMP Environment

4. ORIC Inhibitor Reverses Immunosuppression Resulting in T-cell Activation and Lysis of MM Cells from Relapsed/Refractory Patients

5. ORIC CD73 Inhibitor Triggers Single Agent Cytotoxicity in R/R MM Cells in Assay Utilizing Entire Bone Marrow Milieu

CONCLUSIONS: ORIC-533 exhibits potent best-in-class properties and is the first oral CD73 inhibitor to enter clinical development for multiple myeloma.

• ORIC-533 is:
  - a highly potent adenosine pathway inhibitor
  - superior in potency relative to comparator adenosine pathway inhibitors, even in high AMP environments
  - capable of activating plasmacytoid dendritic cells and increasing T-cell activation
  - able to trigger lysis of relapsed/refractory multiple myeloma cells as a single agent in autograft ex vivo assays

ORIC-533 Phase 1 Clinical Trial (NCT05227144) is Enrolling Patients with Multiple Myeloma

AACR Annual Meeting, April 8-13, 2023

Abstract #2074